APEPTICO - Innovation in peptide drugs

APEPTICO received the FemPower Award of the City of Vienna.

Vienna, Austria, 28th July 2017: APEPTICO, a privately held biotechnology company developing peptide drugs, today announced it has received a FemPower Award sponsored by the City of Vienna.

During a City of Vienna-open business & project competition, the APEPTICO team has applied for the prestigious “FemPower Award”. The “FemPower Award” makes special recognition to female team-leaders and project-members in science and industry. Within the applied project, Dr. Susan Tzotzos from APEPTICO has taken the role of the project co-ordinator. With the FemPower call, research projects are supported which are either directed by women or whose implementation is decisively performed by women. The “FemPower Award” also recognised APEPTICO’s yearlong collaboration with the research group of Prof. Dr. Rosa Lemmens-Gruber from the Department of Pharmacology and Toxicology of the University Vienna.

APEPTICO is using the non-diluting and non-refundable grant to strengthening the scientific collaboration with the Department of Pharmacology and Toxicology of the University Vienna. The joined scientific research team of APEPTICO and the Department of Pharmacology and Toxicology the University Vienna explorse additional medical therapeutic application of Solnatide, a highly specific sodium ion channel modulator.

 

Read more...


Apeptico Forschung und Entwicklung GmbH and Mediolanum farmaceutici S.p.A. today announce the signing of a Research & Development Cooperation and License Agreement for Apeptico’s compound Solnatide.

Vienna, Austria and Milano, Italy, 2nd December 2016 - Apeptico Forschung und Entwicklung GmbH and Mediolanum farmaceutici S.p.A. today announce the signing of a Research & Development Cooperation and License Agreement for Apeptico's compound solnatide. Solnatide is a therapeutic peptide developed by Apeptico for the activation of alveolar liquid clearance, ready to enter into phase IIb clinical development for different life-threatening pulmonary indications.

Under the Agreement, Apeptico will receive an up-front research & development payment in cash, development milestones, and will supply Mediolanum the finished pharmaceutical product. In return, Mediolanum will receive an exclusive license for solnatide for various European markets.

Read more...


Read All 2016 Press Releases

Vienna, Austria and Milano, Italy, 2nd December 2016 - Apeptico Forschung und Entwicklung GmbH and Mediolanum farmaceutici S.p.A. today announce the signing of a Research & Development Cooperation and License Agreement for Apeptico's compound solnatide. Solnatide is a therapeutic peptide developed by Apeptico for the activation of alveolar liquid clearance, ready to enter into phase IIb clinical development for different life-threatening pulmonary indications.

Vienna, Austria, 15th November 2016: APEPTICO, a privately held biotechnology company developing peptide drugs, today announced that in collaboration with Professor Zhou Qiquan from the Medical University in Chongqing it has produced breakthrough scientific results for the use of solnatide for the treatment of High Altitude Pulmonary Oedema (HAPE).

9th February 2016, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a
biotechnology company developing novel peptide-based drugs, today announced that its
development compound Solnatide has been granted Orphan Drug Designation for
"Treatment of Primary Graft Dysfunction following Lung Transplantation" and for
"Treatment of Pseudohypoaldosteronism Type 1B" by the Food and Drug Administration.

Read more...

Read All 2015 Press Releases

1st December 2015, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that its development compounds AP301 (INN: Solnatide) and AP318 have been granted orphan drug designation by the Committee for Orphan Medicinal Products of the European Medicines
Agency for treatment of Pseudohypoaldosteronism Type 1B.

5th October 2015, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that its development compound AP301 has been granted orphan drug designation by the Committee for Orphan Medicinal Products of the European Medicines Agency for the orphan indication ‘treatment of primary graft dysfunction following lung transplantation'.

Vienna, Austria, 1st June 2015: APEPTICO, a privately held biotechnology company developing peptide drugs, today announced that it has succeeded in the technical development of carrier-free protein-only dry powder inhalation particles.
Vienna, Austria, 3rd March 2015: APEPTICO, a privately held biotechnology company developing peptide drugs, today announced that the phase IIa clinical study of AP301-peptide delivered topline results in the treatment of primary graft dysfunction in patients following lung transplantation.

Vienna, Austria, 18th February 2015: APEPTICO, a privately-held biotechnology company
developing synthetic protein structures, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed the phase III clinical development strategy for APEPTICO's AP301-peptide in the orphan condition Acute Respiratory Distress Syndrome.

Vienna, Austria, 2nd January 2015: APEPTICO, a privately-held biotechnology company developing synthetic protein structures, today announced that it has been awarded a research grand by the Wellcome Trust under the Pathfinder Award scheme to further explore the role of APEPTICO's compound ‘Enaritide' for the treatment of Pseudohypoaldosteronism type 1b (PHA type 1b).

Read more...

Read All 2014 Press Releases

Vienna, Austria, 1st December 2014: APEPTICO, a privately-held biotechnology company developing peptide drugs, today announced that it will present major scientific break-through results for its AP301-peptide based inhalation medicine at leading international conferences in December this year.

Vienna, Austria, September 16th, 2014. Most recently, in a scientific collaboration effort between APEPTICO, the Vascular Biology Center of the Georgia Regents University (Prof. Dr. Rudolf Lucas, USA), and the Institute of Pharmacology and Toxicology of the University of Vienna (Prof. Dr. Rosa Lemmens-Gruber, Austria), the detailed mechanism has been discovered how APEPTICO's clinically stage "AP301-peptide" (identical to the lectin-like domain of native TNF-alpha) activates the specific pulmonary ion channel "ENaC" to result in "Activation of Lung Oedema Clearance".

Vienna, Austria, 16th July, 2014: APEPTICO, a privately held biotechnology company developing peptide drugs, today announced that Dr. Rudolf Lucas, co-founder of APEPTICO and Professor of Pharmacology and Toxicology at the Vascular Biology Center, Medical College of Georgia, Georgia Regents University, has produced breakthrough results in the scientific understanding of alveolar liquid clearance regulation by the apically expressed pulmonary epithelial sodium channel (ENaC).
Vienna, Austria, April 9th, 2014: APEPTICO, a privately held biotechnology company developing peptide drugs, today announced that the phase IIa clinical study of AP301 delivered top-line results in the treatment of pulmonary permeability oedema in mechanically ventilated patients suffering from Acute Respiratory Distress Syndrome.

Vienna, Austria, March 13th, 2014: APEPTICO, a privately-held biotechnology company developing peptide drugs, today announced that the target selection team at Global Medical Discovery has identified our publication "Mechanism of Action of Novel Lung Edema Therapeutic AP301 by Activation of the Epithelial Sodium Channel" as a key scientific article contributing to excellence in biomedical research.

Read more...

Read All 2013 Press Releases

Vienna, Austria, December 3rd, 2013: APEPTICO, a privately-held biotechnology company developing peptide drugs, today announced that significant scientific results of its development compound AP301 have been published in Molecular Pharmacology and The Journal of Clinical Pharmacology, summarising the mode of action of AP301 in activating the amiloride-sensitive epithelial sodium ion channel (ENaC) and presenting the results of APEPTICO's first-in-man clinical study of orally inhaled AP301.

Vienna, Austria, October 23, 2013 - APEPTICO, a privately-held biotechnology company developing peptide drugs, today announced that it has entered into a license agreement with Chem Tech Research Incorporation (C-TRI), where APEPTICO will provide C-TRI with a non-exclusive license to APEPTICO's database PEPBASE(TM). Under terms of the Agreement, APEPTICO will receive a license fee and annual payments from C-TRI for data base updates.

Vienna, Austria, July 8, 2013 - APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASETM discovery technology, today announced that it has received a research grant worth more than EUR 500,000 from the Austrian Research Promotion Agency (FFG) to accelerate the clinical assessment of the AP301 peptide in patients following lung transplantation.

Vienna, Austria, April 17, 2013 - APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASETM discovery technology, today announced that the Ethics Committee of the Medical University of Vienna has approved the company's application to perform a phase IIa clinical study in male and female patients following lung transplantation to investigate the clinical effect of repetitive orally inhaled doses of AP301 on primary graft dysfunction.

Vienna, Austria, 31st January, 2013: Apeptico Forschung und Entwicklung GmbH announced that the recent publication of an article in the journal Pulmonary Pharmacology and Therapeutics, describing the effect of APEPTICO's lead compound, AP301, in primary dog, pig and rat cells, marked the culmination of another successful year in the Company's R&D programme.

18th January, 2013, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that its development compound AP301 has been granted orphan-drug designation by the Committee for Orphan Medicinal Products (European Medicines Agency, EC) and by the Office of
rphan Product Development (Food and Drug Administration, USA) for the clinical indication "treatment of High Altitude Pulmonary Oedema".

Read more...

Read All 2012 Press Releases

31st August, 2012, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that it will present most recent clinical research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2012 Annual Congress of the European Respiratory Society.

Vienna, Austria, June 29, 2012 - APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASETM discovery technology, today announced the initiation of a proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance.

16th May, 2012, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a EUR 3.4 million financing round. This equity financing combined existing and new private and institutional investors, as well as a research grant from the Austrian Research
Promotion Agency (FFG).

10th May, 2012, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that it will present early clinical development results of its inhalation therapy for prevention and treatment of oedematous respiratory failure at the 2012 International Conference of the American Thoracic Society.

Vienna, Austria, 26th January, 2012- The patent "Prevention and Treatment of Hyperpermeability" invented and owned by APEPTICO GmbH ranks among the 10 most innovative inventions of the year 2011 in Austria. Today, APEPTICO's patent AT_507_953 was awarded the INVENTUM nomination based on a decision of a jury composed of patent experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology.

Read more...

Read All 2011 Press Releases

Vienna, Austria, 25th October, 2011- APEPTICO GmbH, a biotechnology company developing peptide drugs based on its PEPBASETM discovery technology, today announced completion of a Phase I clinical trial for its pulmonary sodium ion channel activator AP301. The orally inhaled drug candidate was safe and well-tolerated by all study participants. AP301 is being developed for the prevention and treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation.

29th September, 2011, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that the 2011 Annual Conference of the European Respiratory Society has been a major success for the company.

9th September, 2011, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that it will present significant research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2011 Annual Congress of the European Respiratory Society.

Vienna, Austria, April 07, 2011 - APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASETM discovery technology, today announced the initiation of a Phase I clinical trial with its lead product AP301 to assess the safety and tolerability of the orally inhaled peptide drug. AP301 is being developed for the treatment of oedematous respiratory failure in patients suffering from lung
infection, lung injury and lung transplantation.

Read more...

Read All 2010 Press Releases

5th August, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a €3 million financing round. This equity financing combined existing and new investors from Germany and Switzerland. As an integral part of the financing round, APEPTICO will receive a €1.2 million research grant from the Austrian Research Promotion Agency (FFG).

23rd February, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it's lead molecule AP301 has been validated in an experimental lung transplantation model where intratracheal application of AP301 dramatically improved oxygenation after lung transplantation.

10th February, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it has received Orphan Dug Designation in the USA from the Food and Drug Administration (FDA) for APEPTICO's development compound AP301. AP301 has been granted Orphan Drug Designation in the USA for "prevention of ischemia reperfusion injury in the lung during lung transplantation".

15th September, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology compan developing a novel peptide-based drug for the treatment of the life threatening disease "Acute Lung Injury" today announced, that it will present its inhalation therapy for prevention and treatment of Acute Lung Injury at the Annual Congress of the European Respiratory Society which starts on 18th September 2010 in Barcelona, Spain.

Read more...

Read All 2009 Press Releases

1st November September, 2009, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing the novel peptide-based drug AP301 for the treatment of the life threatening disease "Acute Lung Injury", announced today that it will participate at the 15th BIO-Europe International Partnering Conference which starts on 2nd November 2009 in Vienna, Austria. APEPTICO will be in the Austrian Biotech Pavilion conducting pre-scheduled face-to-face meetings.

8th September, 2009, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing a novel peptide-based drug for the treatment of the life threatening disease "Acute Lung Injury" today announced, that it will present its most recent scientific results for APEPTICO's lead compound AP301 at the Annual Congress of the European Respiratory Society which starts on 12th September 2009 in Vienna, Austria.

20th July, 2009, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it has received Orphan Medicinal Product Designation in the European Union from the European Medicines Agency (EMEA) for APEPTICO's lead product AP301 ("Human tumour necrosis
factor alpha-derived peptide") for the "treatment of Acute Lung Injury".

9th June 2009, Wien, Österreich: APEPTICO Forschung und Entwicklung GmbH teilt mit, dass das Unternehmen anlässlich der Verleihung des "Venture Capital & Private Equity Award Österreichs" mit einem Preis ausgezeichnet wurde. Dieser Preis wurde durch den „Styria Börse Express" und die „Junge Industrie" verliehen und stellt eine Anerkennung für die kürzlich abgeschlossene Finanzierung des Unternehmens durch Investoren und Österreichische Fördergeber dar.

29th May, 2009, Vienna, Austria: APEPTICO, a biotechnology company developing novel peptide-based drugs, announced completion of a seed financing round. The EUR 1 Mio equity financing round was led by The BioScience Ventures Group AG (BSVG, www.bsvg.com, Munich/Germany) and included the participation of the Swiss business angel Dr. Jürg Geigy. Both, BSVG and Dr. Geigy are specialised in early stage investments in the biotech industry. The completion of the financing round entitled APEPTICO to receive a grant of EUR 1.2 Mio from the Austrian Research Promotion Agency (FFG).

March 26th, 2009, Venna, Austria. Medical breakthrough for treatment of Acute Lung Injury. Based on intensive research and comprehensive in-vitro and in-vivo studies APEPTICO Forschung und Entwicklung GmbH, a Vienna development stage biotechnology company, has clarified the mode of action of its development compound AP301. Up to date there exists no approved drug molecule for the treatment of Acute Lung Injury. Up to 100,000 patients in Europe could benefit from the new discovery.

Read more...